An Open-Label Phase 1/2 Trial to Evaluate the Safety, Tolerability, and Efficacy of MORAb 202 in Subjects with Selected Tumor Types.

You likely can't join if

• 1 Have endometrial leiomyosarcoma, endometrial stromal sarcoma other soft tissue sarcoma histology. 2-Received previous treatment with any folate receptor targeting agents,except for mirvetuximab soravtansine in the setting of FRA ≥75%. 3- Have platinum refractory OC. 4-Currently enrolled in another clinical study or used any investigational drug or device as defined in the protocol. 5- With brain or subdural metastases (as defined in the protocol) are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 2 weeks before starting treatment in this study. 6-Diagnosed with meningeal carcinomatosis. 7-Any other invasive malignancy that required treatment (other than definitive surgery) or has shown evidence of recurrence/progression (except for non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ) during the 2 years before prior to starting study treatment. 8-Significant cardiovascular impairment. 9-Clinically significant ECG abnormality. 10-Known to be HIV positive. 11-Active viral hepatitis (B or C as demonstrated by positive serology). 12-Females who are breastfeeding or pregnant at Screening or Baseline. 13-Females of childbearing potential who: -within 28 days before study entry, did not use a highly effective method of contraception, as set out in the protocol. -do not agree to use a highly effective method of contraception (as set out in the protocol) throughout the entire study period and for 7 months after study drug discontinuation. 14-For Dose-Escalation only: Males who have not had a successful vasectomy or they and their female partners do not meet the criteria above (refer to the protocol). 15-Pulmonary Function Test (PFT) abnormalities: FEV1/FVC <0.7, FEV1 or FVC <80%, DLCO <80%or less than the lower limit of normal according to local institutional standards. 16-Current ILD/pneumonitis, or ILD/pneumonitis is suspected at Screening or history of ILD/pneumonitis of any severity including ILD/pneumonitis from prior anticancer therapy. 17-Current infectious pneumonia, history of viral pneumonia with evidence of persistent radiologic abnormalities. 18-Lung-specific clinically significant illnesses and restrictive lung disease or currently receiving any medication that is associated with a clinically significant risk of developing ILD. 19-Clinically significant pleural or pericardial effusion requiring drainage or ascites requiring peritoneal shunt. 20-Prior pneumonectomy.
• 21-History of chest radiotherapy. Subjects with history of chest wall radiation (eg, history of breast cancer) may be permitted if chest wall radiation is documented > 2 years before starting study treatment. 22-Any autoimmune, connective tissue, or inflammatory disorders where there is documented (or suspicion of) pulmonary involvement. 23-A known history of active TB (bacillus tuberculosis). 24-Scheduled for surgery during the study, other than minor surgery which would not delay study treatment. 25-An active clinically significant (in the opinion of the Investigator) infection requiring systemic therapy within 2 weeks before the first dose of study drug. 26-Administration of a live, attenuated vaccine within 4 weeks before the first dose of study drug, or anticipation that such a live attenuated vaccine will be required during the study. 27-Any prior hypersensitivity to monoclonal antibodies and/or contraindication to the receipt of corticosteroids or any of the excipients 28-Known intolerance to either of the components of the study drug. 29-Any medical or other condition which, in the opinion of the investigator would preclude the subject's participation in the clinical study. 30-Receiving any medication prohibited in combination with the study treatment(s), as described in the product label for eribulin, unless medication was stopped within 7 days before enrollment. 31-Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• In addition, for Dose Optimization Part B subjects who receive MORAb-202 in combination with Lenvatinib: 32. If >1+ proteinuria on dipstick, 24-hour urine protein is ≥1 g 33. Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib. 34. Unable to take oral medication. 35. Major surgery within 3 weeks before the first dose of study treatment. 36. Have a serious nonhealing wound, ulcer or bone fracture. 37. Pre-existing Grade ≥3 gastrointestinal (GI) or non-GI fistula. 38.Subjects having radiographic evidence of major blood vessel invasion/infiltration.